{"success":true,"data":{"pressRelease":{"id":"142723","rtpr_id":"nGNX5M6FGs-20260914","ticker":"NTHI","exchange":"NASDAQ","all_tickers":["NTHI"],"title":"Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test","author":"Globe Newswire","published_at":"2026-09-14T13:07:02.103Z","article_body":"DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc\nTechnologies Holdings (NASDAQ: NTHI) is sending investors a signal that is\nimpossible to ignore.\n\nThe company's CEO, President and director, Amir F. Heshmatpour, just bought\nanother 37,000 shares of NTHI at $3.6654 apiece, putting approximately\n$136,000 of his own money behind the stock and the timing is what makes this\npurchase particularly intriguing.\n\nNeOnc had just announced a $15 million registered direct offering at $4.20 per\nshare, meaning Heshmatpour's latest purchase occurred at a substantial\ndiscount to the financing price.\n\nThat is not the kind of insider transaction small-cap biotech traders casually\ndismiss.\n\nHeshmatpour has been buying NTHI repeatedly and he isn't the only insider who\nhas been putting money behind the company. In August, Heshmatpour bought\nadditional shares, while founder and Chief Scientific Officer Thomas C. Chen\nalso made substantial purchases.\n\nThe Clinical Catalyst\n\nNeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant\nhigh-grade glioma. The company reported a 48.9% six-month progression-free\nsurvival rate, versus a pre-specified 20% benchmark.\n\nEven more eye-catching: the company reported a 26.09-month median overall\nsurvival.\n\nFive of 24 patients remained on treatment at the data cutoff, including one\npatient with progression-free survival approaching 19 months and another with\nan ongoing partial response. For a company operating in one of oncology's\ntoughest areas, those numbers naturally attracted attention, but the real\nstory may be what comes next.\n\nNeOnc says it plans to request a Type B meeting with the FDA to discuss the\npotential registrational path for NEO100. CEO Heshmatpour said the company's\npriority is “to engage with the FDA and align on the most efficient path\ntoward a registrational study,” which is a major potential inflection point.\n\nIf FDA discussions produce a viable path forward, NEO100 could move from an\nintriguing clinical-stage asset toward a potentially registrational\ndevelopment program, which makes the insider buying even more interesting,\nbecause Heshmatpour is buying after clinical data have been released and while\nthe company is pursuing regulatory discussions.\n\nThe Blood-Brain Barrier\n\nThere is another piece investors cannot ignore: the blood-brain barrier.\n\nBrain tumors are notoriously difficult to treat because getting drugs into the\nbrain is itself a major challenge. NeOnc's NEO100 program uses intranasal\ndelivery designed to facilitate delivery to the brain through olfactory and\ntrigeminal pathways.\n\nIf that approach can translate into meaningful clinical benefit, the\nopportunity could extend well beyond one small study.\n\nNEO100's Phase 2a study was small, open-label and single-arm. Larger studies\nare needed. FDA discussions do not guarantee a registrational pathway, or\napproval.\n\nThe company has simultaneously been advancing NEO100 and NEO212, raising\ncapital and moving toward additional clinical and regulatory milestones.\n\nFor investors hunting for small-cap biotech names before major catalysts,\nthat's the part of the story that deserves attention, and if NEO100's clinical\nsignal ultimately translates into a successful registrational program, today's\ninsider buying could look considerably more significant in hindsight.\n\nAbout 24/7 Market News\n\nIn today's fast-moving markets, visibility is everything and 24/7 Market News\n(24/7) provides a powerful suite of investor relations and public relations\nsolutions designed to elevate your company’s profile quickly and\neffectively. Whether you're an established name seeking broader awareness, or\na micro-cap looking to break out of obscurity, 24/7 delivers targeted,\nhigh-impact coverage through timely news distribution, analyst report\nplacements, featured editorials, and multi-channel amplification across\nfinancial platforms, social media, and investor communities. Our services help\ncut through the noise, attract institutional interest, drive exposure, and\nbuild long-term shareholder credibility, all while maintaining full SEC\ncompliance and transparency. For Analyst Report coverage, custom IR campaigns,\npress release syndication, or other tailored investor and public relations\nsolutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate\nyour company’s visibility and valuation trajectory.\n\nThis is a paid editorial communication intended for informational purposes\nonly. 24/7 is compensated by NTHI to provide ongoing news coverage of expected\nupcoming catalysts and events as well as market outreach services. For further\ndisclosure information, please click here\n(https://www.globenewswire.com/Tracker?data=4svQWiO40j4udSSrvTNFWji1kv7q4vzLHqIm0PnmfverivIBadNfARupnc8-8RqNxpX3Fml8a_lV3KIYwv7Z1vAMhdrn3MduQ6RZOR2jMwQ=).\nThis should not be construed as financial or investment advice. Trading\ninvolves substantial risk; consult your financial advisor.\n\nImportant Editorial Note: 247 highlights companies approaching significant\ncatalysts and inflection points. This report reflects information available at\nthe time of publication. Since developments can occur rapidly, readers should\nindependently verify current information and review all company filings and\ndisclosures.\n\nCONTACT:\n24/7 Market News\nEditor@247mnn.com\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f91276c-d820-4666-8efc-2d8786490903)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5M6FGs-20260914","title":"Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test","author":"Globe Newswire","ticker":"NTHI","created":"2026-09-14T13:07:02.103Z","tickers":["NTHI"],"exchange":"NASDAQ","article_body":"DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc\nTechnologies Holdings (NASDAQ: NTHI) is sending investors a signal that is\nimpossible to ignore.\n\nThe company's CEO, President and director, Amir F. Heshmatpour, just bought\nanother 37,000 shares of NTHI at $3.6654 apiece, putting approximately\n$136,000 of his own money behind the stock and the timing is what makes this\npurchase particularly intriguing.\n\nNeOnc had just announced a $15 million registered direct offering at $4.20 per\nshare, meaning Heshmatpour's latest purchase occurred at a substantial\ndiscount to the financing price.\n\nThat is not the kind of insider transaction small-cap biotech traders casually\ndismiss.\n\nHeshmatpour has been buying NTHI repeatedly and he isn't the only insider who\nhas been putting money behind the company. In August, Heshmatpour bought\nadditional shares, while founder and Chief Scientific Officer Thomas C. Chen\nalso made substantial purchases.\n\nThe Clinical Catalyst\n\nNeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant\nhigh-grade glioma. The company reported a 48.9% six-month progression-free\nsurvival rate, versus a pre-specified 20% benchmark.\n\nEven more eye-catching: the company reported a 26.09-month median overall\nsurvival.\n\nFive of 24 patients remained on treatment at the data cutoff, including one\npatient with progression-free survival approaching 19 months and another with\nan ongoing partial response. For a company operating in one of oncology's\ntoughest areas, those numbers naturally attracted attention, but the real\nstory may be what comes next.\n\nNeOnc says it plans to request a Type B meeting with the FDA to discuss the\npotential registrational path for NEO100. CEO Heshmatpour said the company's\npriority is “to engage with the FDA and align on the most efficient path\ntoward a registrational study,” which is a major potential inflection point.\n\nIf FDA discussions produce a viable path forward, NEO100 could move from an\nintriguing clinical-stage asset toward a potentially registrational\ndevelopment program, which makes the insider buying even more interesting,\nbecause Heshmatpour is buying after clinical data have been released and while\nthe company is pursuing regulatory discussions.\n\nThe Blood-Brain Barrier\n\nThere is another piece investors cannot ignore: the blood-brain barrier.\n\nBrain tumors are notoriously difficult to treat because getting drugs into the\nbrain is itself a major challenge. NeOnc's NEO100 program uses intranasal\ndelivery designed to facilitate delivery to the brain through olfactory and\ntrigeminal pathways.\n\nIf that approach can translate into meaningful clinical benefit, the\nopportunity could extend well beyond one small study.\n\nNEO100's Phase 2a study was small, open-label and single-arm. Larger studies\nare needed. FDA discussions do not guarantee a registrational pathway, or\napproval.\n\nThe company has simultaneously been advancing NEO100 and NEO212, raising\ncapital and moving toward additional clinical and regulatory milestones.\n\nFor investors hunting for small-cap biotech names before major catalysts,\nthat's the part of the story that deserves attention, and if NEO100's clinical\nsignal ultimately translates into a successful registrational program, today's\ninsider buying could look considerably more significant in hindsight.\n\nAbout 24/7 Market News\n\nIn today's fast-moving markets, visibility is everything and 24/7 Market News\n(24/7) provides a powerful suite of investor relations and public relations\nsolutions designed to elevate your company’s profile quickly and\neffectively. Whether you're an established name seeking broader awareness, or\na micro-cap looking to break out of obscurity, 24/7 delivers targeted,\nhigh-impact coverage through timely news distribution, analyst report\nplacements, featured editorials, and multi-channel amplification across\nfinancial platforms, social media, and investor communities. Our services help\ncut through the noise, attract institutional interest, drive exposure, and\nbuild long-term shareholder credibility, all while maintaining full SEC\ncompliance and transparency. For Analyst Report coverage, custom IR campaigns,\npress release syndication, or other tailored investor and public relations\nsolutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate\nyour company’s visibility and valuation trajectory.\n\nThis is a paid editorial communication intended for informational purposes\nonly. 24/7 is compensated by NTHI to provide ongoing news coverage of expected\nupcoming catalysts and events as well as market outreach services. For further\ndisclosure information, please click here\n(https://www.globenewswire.com/Tracker?data=4svQWiO40j4udSSrvTNFWji1kv7q4vzLHqIm0PnmfverivIBadNfARupnc8-8RqNxpX3Fml8a_lV3KIYwv7Z1vAMhdrn3MduQ6RZOR2jMwQ=).\nThis should not be construed as financial or investment advice. Trading\ninvolves substantial risk; consult your financial advisor.\n\nImportant Editorial Note: 247 highlights companies approaching significant\ncatalysts and inflection points. This report reflects information available at\nthe time of publication. Since developments can occur rapidly, readers should\nindependently verify current information and review all company filings and\ndisclosures.\n\nCONTACT:\n24/7 Market News\nEditor@247mnn.com\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f91276c-d820-4666-8efc-2d8786490903)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-14T13:07:02.155548763Z","server_sent_at_ms":1789391222155},"received_at":"2026-09-14T13:07:02.210Z","source_url":null},"analysis":{"id":"131556","press_release_id":"142723","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Paid promotional content: 24/7 Market News is compensated by NTHI for ongoing coverage — this is an IR/marketing piece, not an issuer disclosure","Clinical data is a recap of previously reported Phase 2a results; study was small (n=24), open-label and single-arm","Insider purchase price of $3.6654 is ~13% below the $4.20 offering price, implying recent dilution","Forward-looking statements boilerplate references the company's ability to continue as a going concern","FDA discussions do not guarantee a registrational pathway or approval"],"eventType":"insider_transaction","narrative":"NeOnc Technologies CEO, President and director Amir F. Heshmatpour bought another 37,000 NTHI shares at $3.6654 apiece — roughly $136,000 — shortly after the company announced a $15 million registered direct offering at $4.20 per share.\n\nFounder and Chief Scientific Officer Thomas C. Chen also made substantial purchases in August, continuing a pattern of repeated insider buying highlighted in the release.\n\nOn the clinical side, NEO100 posted a 48.9% six-month progression-free survival rate in recurrent IDH1-mutant high-grade glioma versus a pre-specified 20% benchmark, with 26.09-month median overall survival, and NeOnc plans to request a Type B FDA meeting on a potential registrational path.\n\nThis is a paid editorial from 24/7 Market News, which is compensated by NTHI; the clinical results are a recap of previously reported topline Phase 2a data from a small, open-label, single-arm study, not new disclosure.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Suppress the paid promo; the real catalyst to watch is the Type B FDA meeting request for NEO100 and whether insiders keep buying."},"keyFigures":{"offeringPrice":4.2,"customDimensions":{"pfs_6mo_rate":"48.9%","offering_size":"$15 million registered direct offering","pfs_benchmark":"20%","phase2a_patients":24,"insider_purchase_shares":37000,"median_overall_survival_months":26.09,"patients_on_treatment_at_cutoff":5,"insider_purchase_price_per_share":3.6654,"insider_purchase_value_usd_approx":136000}},"quotedText":"to engage with the FDA and align on the most efficient path","namedEntities":{"people":[{"name":"Amir F. Heshmatpour","role":"CEO, President and director of NeOnc Technologies"},{"name":"Thomas C. Chen","role":"Founder and Chief Scientific Officer"}],"products":["NEO100","NEO212"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI","relationship":"filer"},{"name":"24/7 Market News","relationship":"paid promoter / IR content provider compensated by NTHI"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$136,000","context":"approximate value of CEO's 37,000-share purchase"},{"amount":"$15 million","context":"registered direct offering size"},{"amount":"$4.20","context":"per-share price of registered direct offering"},{"amount":"$3.6654","context":"per-share price of CEO insider purchase"}]},"materialImpact":{"score":2,"reasoning":"A CEO open-market purchase of roughly $136,000 and a recap of previously reported Phase 2a data for a micro-cap biotech are directionally positive but modest in size, and this is a paid third-party editorial rather than an issuer disclosure. The planned Type B FDA meeting request is a genuine future catalyst but has not occurred yet."},"tickerRelevance":{"others":[],"primary":"NTHI"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial","regulatory"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"insider-buying-recap-in-paid-promo","promoContent":true,"issuerAuthored":false,"upcomingCatalyst":"FDA Type B meeting request","clinicalAssetStage":"Phase 2a"}},"event_type":"insider_transaction","event_type_secondary":["clinical_trial","regulatory"],"sentiment":"bullish","material_impact_score":2,"narrative":"NeOnc Technologies CEO, President and director Amir F. Heshmatpour bought another 37,000 NTHI shares at $3.6654 apiece — roughly $136,000 — shortly after the company announced a $15 million registered direct offering at $4.20 per share.\n\nFounder and Chief Scientific Officer Thomas C. Chen also made substantial purchases in August, continuing a pattern of repeated insider buying highlighted in the release.\n\nOn the clinical side, NEO100 posted a 48.9% six-month progression-free survival rate in recurrent IDH1-mutant high-grade glioma versus a pre-specified 20% benchmark, with 26.09-month median overall survival, and NeOnc plans to request a Type B FDA meeting on a potential registrational path.\n\nThis is a paid editorial from 24/7 Market News, which is compensated by NTHI; the clinical results are a recap of previously reported topline Phase 2a data from a small, open-label, single-arm study, not new disclosure.","key_figures":{"offeringPrice":4.2,"customDimensions":{"pfs_6mo_rate":"48.9%","offering_size":"$15 million registered direct offering","pfs_benchmark":"20%","phase2a_patients":24,"insider_purchase_shares":37000,"median_overall_survival_months":26.09,"patients_on_treatment_at_cutoff":5,"insider_purchase_price_per_share":3.6654,"insider_purchase_value_usd_approx":136000}},"named_entities":{"people":[{"name":"Amir F. Heshmatpour","role":"CEO, President and director of NeOnc Technologies"},{"name":"Thomas C. Chen","role":"Founder and Chief Scientific Officer"}],"products":["NEO100","NEO212"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI","relationship":"filer"},{"name":"24/7 Market News","relationship":"paid promoter / IR content provider compensated by NTHI"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$136,000","context":"approximate value of CEO's 37,000-share purchase"},{"amount":"$15 million","context":"registered direct offering size"},{"amount":"$4.20","context":"per-share price of registered direct offering"},{"amount":"$3.6654","context":"per-share price of CEO insider purchase"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T13:07:40.517Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"insider-buying-recap-in-paid-promo","promoContent":true,"issuerAuthored":false,"upcomingCatalyst":"FDA Type B meeting request","clinicalAssetStage":"Phase 2a"}},"durationMs":38300,"modelName":"glm-5.3-flash"}}